NCT03329001: Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule

NCT03329001
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic uncontrolled brain or leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT03329001

Comments are closed.

Up ↑